Bausch + Lomb's Q4 2024: Contradictions in Growth Expectations, Miebo Coverage, and Xiidra Performance

These are the key contradictions discussed in Bausch + Lomb's latest 2024Q4 earnings call, specifically including: Growth Expectations and Market Conditions, Managed Care Coverage for MIEBO, and Xiidra's Integration and Performance:



Revenue Growth and Market Share:
- Bausch + Lomb reported 17% constant currency revenue growth for the year, contributing to double-digit constant currency revenue growth for the fifth consecutive quarter.
- The growth was driven by introducing new products, optimizing manufacturing processes, and leveraging digital tools for increased customer engagement.

Dry Eye Portfolio Expansion:
- The company's dry eye portfolio approached $1 billion in annual revenue, with nearly 50% year-over-year growth in organic revenue.
- This growth was fueled by effective direct-to-consumer campaigns and strong prescriber education for both Miebo and Xiidra.

Contact Lens Performance:
- Bausch + Lomb's contact lens revenue grew 11% for the year, with strong performance across modalities, brands, and geographies.
- Growth was broad-based, driven by the Daily SiHy lens and the company's e-commerce platform, Opal, which opened new distribution channels.

Premium IOL and Surgical Segment Growth:
- The surgical segment saw 11% organic revenue growth, driven by 19% growth in premium IOLs and 21% growth in equipment sales.
- The growth in premium IOLs was attributed to new product launches like Envy and LuxLife, which are being well-received by surgeons and patients.